Technical Analysis for CARA - Cara Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
15.54 | -1.02% | -0.16 |
CARA closed down 1.02 percent on Wednesday, December 12, 2018, on 85 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical CARA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Dec 12 | NR7 | Range Contraction | 0.00% |
| Dec 12 | Lower Bollinger Band Walk | Weakness | 0.00% |
| Dec 12 | Below Lower BB | Weakness | 0.00% |
| Dec 12 | Down 3 Days in a Row | Weakness | 0.00% |
| Dec 12 | Down 4 Days in a Row | Weakness | 0.00% |
| Dec 12 | Down 5 Days in a Row | Weakness | 0.00% |
| Dec 12 | Lower Bollinger Band Touch | Weakness | 0.00% |
| Dec 12 | Oversold Stochastic | Weakness | 0.00% |
| Dec 11 | Lower Bollinger Band Walk | Weakness | -1.02% |
| Dec 11 | Inside Day | Range Contraction | -1.02% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-06
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more CARA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 24.3 |
| 52 Week Low | 11.46 |
| Average Volume | 543,182 |
| 200-Day Moving Average | 17.1463 |
| 50-Day Moving Average | 18.9244 |
| 20-Day Moving Average | 17.834 |
| 10-Day Moving Average | 17.205 |
| Average True Range | 0.9135 |
| ADX | 35.43 |
| +DI | 8.1423 |
| -DI | 29.4608 |
| Chandelier Exit (Long, 3 ATRs ) | 17.5995 |
| Chandelier Exit (Short, 3 ATRs ) | 18.1305 |
| Upper Bollinger Band | 20.0747 |
| Lower Bollinger Band | 15.5933 |
| Percent B (%b) | -0.01 |
| BandWidth | 25.128406 |
| MACD Line | -0.8773 |
| MACD Signal Line | -0.6017 |
| MACD Histogram | -0.2756 |
| Fundamentals | Value |
|---|---|
| Market Cap | 506.3 Million |
| Num Shares | 32.6 Million |
| EPS | -2.28 |
| Price-to-Earnings (P/E) Ratio | -6.82 |
| Price-to-Sales | 424.16 |
| Price-to-Book | 3.54 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.35 | ||||
| Resistance 3 (R3) | 16.41 | 16.21 | 16.22 | ||
| Resistance 2 (R2) | 16.21 | 16.00 | 16.18 | 16.17 | |
| Resistance 1 (R1) | 15.87 | 15.87 | 15.77 | 15.81 | 16.12 |
| Pivot Point | 15.67 | 15.67 | 15.62 | 15.64 | 15.67 |
| Support 1 (S1) | 15.33 | 15.46 | 15.23 | 15.27 | 14.96 |
| Support 2 (S2) | 15.13 | 15.33 | 15.10 | 14.91 | |
| Support 3 (S3) | 14.79 | 15.13 | 14.87 | ||
| Support 4 (S4) | 14.73 |
